All In Biotech

Drug Trial Radar · NCT06551129

Real-world Patient Reported Outcomes Among Patients Treated With Camzyos

Real-World Camzyos Patient Reported OutcoMes Through PAtient SurveyS in Hypertrophic CardioMyopathy (COMPASS-HCM): A Prospective Longitudinal Study

Last checked: Nov 20, 2026Latest source record: Nov 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

118

Planned (sponsor's estimate)

Start

May 10, 2024

Primary completion

Dec 31, 2026

Study completion Jun 30, 2027

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Aug 13, 2024

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This real-world study will assess changes in health status among participants with symptomatic obstructive hypertrophic cardiomyopathy who are treated with mavacamten in the real world.

Conditions

  • Obstructive Hypertrophic Cardiomyopathy

Interventions

  • MavacamtenDrug

    As prescribed by treating physician

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Participant Hypertrophic Cardiomyopathy symptoms as assessed by Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ v2,0 - 7-day recall version)Time frame: Baseline and weeks 2, 4, 8, 12, 24, 30, 48, 60, 72, 84 and 96
  2. Participant physical limitation, symptom stability, symptom frequency, symptom burden, self-efficacy, QoL, and social limitations as assessed by Kansas City Cardiomyopathy Questionnaire (KCCQ-23)Time frame: Baseline and weeks 2, 4, 8, 12, 24, 30, 48, 60, 72, 84 and 96
  3. Participant mavacamten treatment statusTime frame: Weeks 2, 4, 8, 12, 24, 30, 48, 60, 72, 84 and 96
  4. Other pharmacological and surgical treatments for obstructive hypertrophic cardiomyopathy (HCM)Time frame: Baseline and weeks 2, 4, 8, 12, 24, 30, 48, 60, 72, 84 and 96
  5. Participant symptom severity as assessed by self-assessed New York Heart Association (SA-NYHA) functional classTime frame: Baseline and weeks 2, 4, 8, 12, 24, 30, 48, 60, 72, 84 and 96
  6. Participant change in symptom severity as assessed by Patient Global Impression of Change (PGI-C)Time frame: Weeks 2, 4, 8, 12, 24, 30, 48, 72, and 96
  7. Participant septal reduction therapyTime frame: Baseline and weeks 12, 30, 48 and 96
  8. Participant major injury or surgery since previous surveyTime frame: Weeks 2, 4, 8, 12, 24, 30, 48, 60, 72, 84 and 96
  9. Participant survey response on experience with CAMZYOS Risk Evaluation and Mitigation Strategy program (REMS) ProgramTime frame: Baseline and weeks 4, 12, 30, 48, 72 and 96
  10. Participant medical historyTime frame: Baseline

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Analysis Group Inc.

    Boston, Massachusetts · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.